Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia”

17 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 17 results

Testing effectiveness (Phase 2)Study completedNCT00857506
What this trial is testing

Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)

Who this might be right for
Alzheimer's DiseaseMild Cognitive Impairment
Avid Radiopharmaceuticals 152
Large-scale testing (Phase 3)Active Not RecruitingNCT03887455
What this trial is testing

Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

Who this might be right for
Early Alzheimer's Disease
Eisai Inc. 1,906
Large-scale testing (Phase 3)Study completedNCT05542953
What this trial is testing

[18F]APN-1607 PET in Subjects With AD Compared to HC

Who this might be right for
Alzheimer's DiseaseMild Cognitive Impairment Due to Alzheimer's DiseaseHealthy Volunteers
APRINOIA Therapeutics 230
Testing effectiveness (Phase 2)Study completedNCT04498650
What this trial is testing

Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD

Who this might be right for
Early Alzheimers DiseaseMild Cognitive Impairment Due to AD
Vivoryon Therapeutics N.V. 259
Large-scale testing (Phase 3)Looking for participantsNCT07422857
What this trial is testing

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

Who this might be right for
Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
JYAMS PET Research & Development Limited 316
Very early researchStudy completedNCT01436188
What this trial is testing

Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease

Who this might be right for
HealthyAlzheimer Disease
Janssen Research & Development, LLC 5
Large-scale testing (Phase 3)Study completedNCT01565382
What this trial is testing

Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)

Who this might be right for
Alzheimer's Disease
Avid Radiopharmaceuticals 40
Testing effectiveness (Phase 2)UnknownNCT04141150
What this trial is testing

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

Who this might be right for
Alzheimer's DiseaseMild Cognitive Impairment Due to Alzheimer's DiseaseHealthy Volunteers
APRINOIA Therapeutics, LLC 130
Large-scale testing (Phase 3)Study completedNCT02016560
What this trial is testing

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects

Who this might be right for
Alzheimer's Disease
Avid Radiopharmaceuticals 383
Not applicableEnrolling By InvitationNCT06245031
What this trial is testing

Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)

Who this might be right for
Alzheimer DiseaseCognitive ImpairmentMild Cognitive Impairment+5 more
Cognito Therapeutics, Inc. 402
Early research (Phase 1)Ended earlyNCT02614131
What this trial is testing

LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

Who this might be right for
HealthyAlzheimer's DiseaseMild Cognitive Impairment
Eli Lilly and Company 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT05399888
What this trial is testing

Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Who this might be right for
Mild Cognitive Impairment Due to Alzheimer's DiseaseAlzheimer's Disease Dementia
Biogen 416
Large-scale testing (Phase 3)Looking for participantsNCT07752784
What this trial is testing

Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.

Who this might be right for
Alzheimer's Disease
JYAMS PET Research & Development Limited 12
Testing effectiveness (Phase 2)Study completedNCT02880956
What this trial is testing

Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease

Who this might be right for
Alzheimer's Disease
AbbVie 453
Early research (Phase 1)Study completedNCT02754830
What this trial is testing

LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)

Who this might be right for
Alzheimer's Disease
Eli Lilly and Company 72
Testing effectiveness (Phase 2)Active Not RecruitingNCT07741526
What this trial is testing

Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)

Who this might be right for
Alzheimer´s Disease
Arctic Therapeutics 33
Large-scale testing (Phase 3)Ended earlyNCT01953601
What this trial is testing

Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)

Who this might be right for
Amnestic Mild Cognitive ImpairmentAlzheimer's DiseaseProdromal Alzheimer's Disease
Merck Sharp & Dohme LLC 1,454